Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks
- PMID: 17963300
- PMCID: PMC4171260
- DOI: 10.3748/wjg.v13.i43.5736
Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks
Abstract
Aim: To study the predictive value of the vegetative-depressive symptoms of the Zung Depression Rating Scale for the occurrence of depression during treatment with peg-interferon alpha-2b of chronic hepatitis C (CHC) patients.
Methods: The predictive value of vegetative-depressive symptoms at 4 wk of treatment for the occurrence of a subsequent diagnosis of major depressive disorder (MDD) was studied in CHC patients infected after substance use in a prospective, multi-center treatment trial in Belgium. The presence of vegetative-depressive symptoms was assessed using the Zung Scale before and 4 wk after the start of antiviral treatment.
Results: Out of 49 eligible patients, 19 (39%) developed MDD. The area under the ROC curve of the vegetative Zung subscale was 0.73, P = 0.004. The sensitivity at a cut-point of > 15/35 was 95% (95% CI: 74-100). The positive predictive value equalled 44% (95% CI: 29-60).
Conclusion: In this group of Belgian CHC patients infected after substance use, antiviral treatment caused a considerable risk of depression. Seven vegetative-depressive symptoms of the Zung scale at wk 4 of treatment predicted 95% of all emerging depressions, at a price of 56% false positive test results.
Figures
Similar articles
-
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.J Clin Psychiatry. 2005 Jan;66(1):41-8. doi: 10.4088/jcp.v66n0106. J Clin Psychiatry. 2005. PMID: 15669887 Free PMC article.
-
Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.Clin Drug Investig. 2006;26(11):655-62. doi: 10.2165/00044011-200626110-00005. Clin Drug Investig. 2006. PMID: 17163300 Clinical Trial.
-
Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.Psychiatr Danub. 2011 Dec;23(4):370-7. Psychiatr Danub. 2011. PMID: 22075738
-
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.Curr Drug Abuse Rev. 2008 Jun;1(2):177-87. doi: 10.2174/1874473710801020177. Curr Drug Abuse Rev. 2008. PMID: 19630716 Review.
-
[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].Encephale. 2005 May-Jun;31(3):349-57. doi: 10.1016/s0013-7006(05)82400-5. Encephale. 2005. PMID: 16142050 Review. French.
Cited by
-
Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?Neurosci Biobehav Rev. 2011 Jan;35(3):742-64. doi: 10.1016/j.neubiorev.2010.09.010. Epub 2010 Sep 29. Neurosci Biobehav Rev. 2011. PMID: 20883718 Free PMC article. Review.
-
Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.Cognit Ther Res. 2019 Aug;43(4):679-692. doi: 10.1007/s10608-018-09990-7. Epub 2019 Feb 12. Cognit Ther Res. 2019. PMID: 31777409 Free PMC article.
-
The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation.Neurosci Biobehav Rev. 2018 Nov;94:219-237. doi: 10.1016/j.neubiorev.2018.09.006. Epub 2018 Sep 7. Neurosci Biobehav Rev. 2018. PMID: 30201219 Free PMC article. Review.
-
Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C.Contemp Clin Trials Commun. 2017 Jun;6:85-96. doi: 10.1016/j.conctc.2017.03.008. Epub 2017 Apr 2. Contemp Clin Trials Commun. 2017. PMID: 29082334 Free PMC article.
-
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?J Consult Clin Psychol. 2013 Apr;81(2):361-74. doi: 10.1037/a0029030. Epub 2012 Jun 25. J Consult Clin Psychol. 2013. PMID: 22730952 Free PMC article. Review.
References
-
- Robaeys G, Buntinx F, Bottieau E, Bourgeois S, Brenard R, Colle I, De Bie J, Matheï C, Mulkay JP, Van Damme P, et al. Guidelines for the management of chronic hepatitis C in patients infected after substance use. Acta Gastroenterol Belg. 2005;68:38–45. - PubMed
-
- Sylvestre D. Hepatitis C treatment in drug users: perception versus evidence. Eur J Gastroenterol Hepatol. 2006;18:129–130. - PubMed
-
- Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18:159–166. - PubMed
-
- Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry. 2003;25:34–38. - PubMed
-
- Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156:1120. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical